<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01708603</url>
  </required_header>
  <id_info>
    <org_study_id>20120103</org_study_id>
    <nct_id>NCT01708603</nct_id>
  </id_info>
  <brief_title>P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis</brief_title>
  <acronym>AMAGINE-2</acronym>
  <official_title>A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of brodalumab at two different
      doses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      .The purpose of this study is to assess the safety and efficacy of brodalumab at two
      different doses compared with placebo in participants with moderate to severe plaque
      psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at
      two different doses compared with ustekinumab in participants with moderate to severe plaque
      psoriasis. A third purpose of this study is to assess the safety and efficacy of 4
      maintenance regimens of brodalumab.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measures the physician's impression of the disease at a single point, and a dynamic form in which the physician assesses the global improvement from baseline. Success is defined by a score of 0 or 1 (clear to almost clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>to evaluate the efficacy of Brodalumab (210mg every 2 weeks, and 140mg every 2 weeks) in subjects with moderate to severe plaque psoriasis, as measured by the proportion of subjects achieving 75% improvement in Psoriasis Area and Severity Index, PASI75 at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>to evaluate the efficacy of Brodalumab (210mg Q2W) in clearing psoriasis as measured by the proportion of subjects achieving PASI 100 at week 12.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1831</enrollment>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>210 mg brodalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140 mg brodalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ustekinumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered by subcutaneous (SC) injection per the labeled dosing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>210 mg brodalumab</intervention_name>
    <description>210 mg brodalumab administered SC</description>
    <arm_group_label>210 mg brodalumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>140 mg brodalumab</intervention_name>
    <description>140 mg brodalumab administered SC</description>
    <arm_group_label>140 mg brodalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ustekinumab</intervention_name>
    <description>45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.</description>
    <arm_group_label>ustekinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has had stable moderate to severe plaque psoriasis for at least 6 months

          -  Subject has involved body surface area (BSA) ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at
             screening and at baseline

        Exclusion Criteria:

          -  Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
             medication-induced psoriasis, or other skin conditions at (eg, eczema) that would
             interfere with study evaluations

          -  Subject has known history of Crohn's disease

          -  Subject has any other significant concurrent medical condition or laboratory
             abnormalities, as defined in the study protocol

          -  Subject has not stopped using certain psoriasis therapies as defined in the study
             protocol

          -  Subject has previously used ustekinumab or any anti-IL-17 biologic therapy

          -  Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in
             the study

          -  Female subject is unwilling to use highly effective methods of birth control unless 2
             years post-menopausal or surgically sterile
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Andover</city>
        <state>Massachusetts</state>
        <zip>01845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gahanna</city>
        <state>Ohio</state>
        <zip>43230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80504</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-658</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4050</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>AndalucÃ-a</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <state>AndalucÃ-a</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <state>AndalucÃ-a</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alcañiz</city>
        <state>AragÃ³n</state>
        <zip>44600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manacor</city>
        <state>Baleares</state>
        <zip>07500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <state>CataluÃ±a</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2012</study_first_posted>
  <results_first_submitted>October 31, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2020</results_first_posted>
  <disposition_first_submitted>April 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 20, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2015</disposition_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis, brodalumab, AMG 827</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Brodalumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>210 mg Brodalumab</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
210 mg brodalumab: 210 mg brodalumab administered SC</description>
        </group>
        <group group_id="P2">
          <title>140 mg Brodalumab</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
140 mg brodalumab: 140 mg brodalumab administered SC</description>
        </group>
        <group group_id="P3">
          <title>Ustekinumab</title>
          <description>Administered by subcutaneous (SC) injection per the labeled dosing regimen.
ustekinumab: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
210 mg brodalumab: 210 mg brodalumab administered SC
placebo: Placebo administered SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
                <participants group_id="P2" count="610"/>
                <participants group_id="P3" count="300"/>
                <participants group_id="P4" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="597"/>
                <participants group_id="P2" count="588"/>
                <participants group_id="P3" count="291"/>
                <participants group_id="P4" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>210 mg Brodalumab</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
210 mg brodalumab: 210 mg brodalumab administered SC</description>
        </group>
        <group group_id="B2">
          <title>140 mg Brodalumab</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
140 mg brodalumab: 140 mg brodalumab administered SC</description>
        </group>
        <group group_id="B3">
          <title>Ustekinumab</title>
          <description>Administered by subcutaneous (SC) injection per the labeled dosing regimen.
ustekinumab: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
210 mg brodalumab: 210 mg brodalumab administered SC
placebo: Placebo administered SC</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="612"/>
            <count group_id="B2" value="610"/>
            <count group_id="B3" value="300"/>
            <count group_id="B4" value="309"/>
            <count group_id="B5" value="1831"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="12.7"/>
                    <measurement group_id="B2" value="44.8" spread="12.8"/>
                    <measurement group_id="B3" value="45.4" spread="13.0"/>
                    <measurement group_id="B4" value="43.7" spread="12.9"/>
                    <measurement group_id="B5" value="44.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="573"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="413"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="219"/>
                    <measurement group_id="B5" value="1258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="551"/>
                    <measurement group_id="B2" value="557"/>
                    <measurement group_id="B3" value="271"/>
                    <measurement group_id="B4" value="273"/>
                    <measurement group_id="B5" value="1652"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="286"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="144"/>
                    <measurement group_id="B5" value="851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12</title>
        <description>Measures the physician's impression of the disease at a single point, and a dynamic form in which the physician assesses the global improvement from baseline. Success is defined by a score of 0 or 1 (clear to almost clear).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>210 mg Brodalumab</title>
            <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
210 mg brodalumab: 210 mg brodalumab administered SC</description>
          </group>
          <group group_id="O2">
            <title>140 mg Brodalumab</title>
            <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
140 mg brodalumab: 140 mg brodalumab administered SC</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
210 mg brodalumab: 210 mg brodalumab administered SC
placebo: Placebo administered SC</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab</title>
            <description>Administered by subcutaneous (SC) injection until week 12. Participants using Ustekinumab were not rerandomized at week 12, and continued to receive ustekinumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12</title>
          <description>Measures the physician's impression of the disease at a single point, and a dynamic form in which the physician assesses the global improvement from baseline. Success is defined by a score of 0 or 1 (clear to almost clear).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="610"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481"/>
                    <measurement group_id="O2" value="354"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12</title>
        <description>to evaluate the efficacy of Brodalumab (210mg every 2 weeks, and 140mg every 2 weeks) in subjects with moderate to severe plaque psoriasis, as measured by the proportion of subjects achieving 75% improvement in Psoriasis Area and Severity Index, PASI75 at week 12.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>210 mg Brodalumab</title>
            <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
210 mg brodalumab: 210 mg brodalumab administered SC</description>
          </group>
          <group group_id="O2">
            <title>140 mg Brodalumab</title>
            <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
140 mg brodalumab: 140 mg brodalumab administered SC</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Brodalumab Placebo</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab</title>
            <description>Administered by subcutaneous (SC) injection until week 12. Participants using Ustekinumab were not rerandomized at week 12, and continued to receive ustekinumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12</title>
          <description>to evaluate the efficacy of Brodalumab (210mg every 2 weeks, and 140mg every 2 weeks) in subjects with moderate to severe plaque psoriasis, as measured by the proportion of subjects achieving 75% improvement in Psoriasis Area and Severity Index, PASI75 at week 12.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="610"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528"/>
                    <measurement group_id="O2" value="406"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12</title>
        <description>to evaluate the efficacy of Brodalumab (210mg Q2W) in clearing psoriasis as measured by the proportion of subjects achieving PASI 100 at week 12.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brodalumab 210mg</title>
            <description>Brodalumab 210mg Q2W</description>
          </group>
          <group group_id="O2">
            <title>Brodalumab 140mg</title>
            <description>Brodalumab 140mg Q2W</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Brodalumab placebo</description>
          </group>
          <group group_id="O4">
            <title>Ustekinumab</title>
            <description>Ustekinumab administered in a dose of 45mg in a prefilled syringe of 0.5mL</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12</title>
          <description>to evaluate the efficacy of Brodalumab (210mg Q2W) in clearing psoriasis as measured by the proportion of subjects achieving PASI 100 at week 12.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="610"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>210 mg Brodalumab</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
210 mg brodalumab: 210 mg brodalumab administered SC</description>
        </group>
        <group group_id="E2">
          <title>140 mg Brodalumab</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
140 mg brodalumab: 140 mg brodalumab administered SC</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab</title>
          <description>Administered by subcutaneous (SC) injection per the labeled dosing regimen.
ustekinumab: 45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
210 mg brodalumab: 210 mg brodalumab administered SC
placebo: Placebo administered SC</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Anteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dysponea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Noncardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Drug Detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Carbon Monoxide Poisining</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cerbebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Joint Capsule Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ligament Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="354" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="365" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="177" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Odema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper respiratory Tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Viral Upper respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Conjuncitvitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muskuloskelital Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Migrane</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pruritus Generalized</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Seborrhoeic Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>510-259-5284</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

